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Editorial
Averting the legacy of kidney disease –  
focus on childhood
JR Ingelfinger, K Kalantar-Zadeh, F Schaefer 
on behalf of the World Kidney Day Steering Committee*
World Kidney Day 2016 focuses on kidney disease in childhood and the antecedents of adult 
kidney disease that can begin in earliest childhood. Chronic kidney disease (CKD) in 
childhood differs from that in adults, as the largest diagnostic group among children includes 
congenital anomalies and inherited disorders, with glomerulopathies and kidney disease in 
the setting of diabetes being relatively uncommon. In addition, many children with acute 
kidney injury will ultimately develop sequelae that may lead to hypertension and CKD in 
later childhood or in adult life. Children born early or who are small-for date newborns have 
relatively increased risk for the development of CKD later in life. Persons with a high-risk 
birth and early childhood history should be watched closely in order to help detect early signs 
of kidney disease in time to provide effective prevention or treatment. Successful therapy is 
feasible for advanced CKD in childhood; there is evidence that children fare better than 
adults, if they receive kidney replacement therapy including dialysis and transplantation, 
while only a minority of children may require this ultimate intervention. Because there are 
disparities in access to care, effort is needed so that those children with kidney disease, 
wherever they live, may be treated effectively, irrespective of their geographic or economic 
circumstances. Our hope is that World Kidney Day will inform the general public, policy 
makers and caregivers about the needs and possibilities surrounding kidney disease in 
childhood.
 “For in every adult there dwells the child that was, and in every child there lies the adult that 
will be.” ― John Connolly, The Book of Lost Things
Introduction and Overview 
The 11th World Kidney Day will be celebrated on March 10, 2016, around the globe. This 
annual event, sponsored jointly by the International Society of Nephrology (ISN) and the 
International Federation of Kidney Foundations (IFKF), has become a highly successful 
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effort to inform the general public and policymakers about the importance and ramifications 
of kidney disease. In 2016, World Kidney Day will be dedicated to kidney disease in 
childhood and the antecedents of adult kidney disease, which can begin in earliest childhood. 
Children who endure acute kidney injury (AKI) from a wide variety of conditions may 
have long-term sequelae that can lead to chronic kidney disease (CKD) many years later 
(1–4). Further, CKD in childhood, much of it congenital, and complications from the many 
non-renal diseases that can affect the kidneys secondarily, not only lead to substantial 
morbidity and mortality during childhood but also result in medical issues beyond childhood. 
Indeed, childhood deaths from a long list of communicable diseases are inextricably linked 
to kidney involvement. For example, children who succumb to cholera and other diarrheal 
infections often die, not from the infection, but because of AKI induced by volume depletion 
and shock. In addition, a substantial body of data indicates that hypertension, proteinuria and 
CKD in adulthood have childhood antecedents – from as early as in utero and perinatal life 
(see Table I for definitions of childhood). World Kidney Day 2016 aims to heighten general 
awareness that much adult renal disease is actually initiated in childhood. Understanding 
high risk diagnoses and events that occur in childhood have the potential to identify and 
intervene preemptively in those people at higher risk for CKD during their lifetimes.
Table I. Definitions of stages of early life
Perinatal period 22 completed weeks of gestation to Day 7 of postnatal life
Neonatal period Birth to Day 28 of postnatal life
Infancy Birth to 1 year of age
Childhood 1 year of age to 10 years of age
Adolescence 10 years of age to 19 years of age
Notes:  The data in this table are as defined by the World Health Organization. The perinatal period is defined  
as 22 completed weeks of gestation to Day 7 of life; the neonatal period, as up to 28 days of life;  
infancy as up to one year of age; childhood as year 1 to 10; and adolescence from 10 years to age 19.
     There is variation worldwide in how these stages of early life are defined. Some would define “young 
people” as those age 24 or less. In the United States, childhood is as a whole defined as going to age 21.
Worldwide epidemiologic data on the spectrum of both CKD and AKI in children are 
currently limited, though increasing in scope. The prevalence of CKD in childhood is rare, 
and has been variously reported at 15–74.7 per million children (3). Such variation is likely 
because data on CKD are influenced by regional and cultural factors, as well as by the 
methodology used to generate them. The World Health Organization (WHO) has recently 
added kidney and urologic disease to mortality information tracked worldwide, and should 
be a valuable source of such data over time — yet WHO does not post the information by age 
group (5). Databases such as the North American Pediatric Renal Trials and Collaborative 
Studies (NAPRTCS) (6), the U.S. Renal Data System (USRDS) (7) and the EDTA registry 
(8) include data on pediatric ESRD, and some on CKD. Projects such as the ItalKid (9) and 
Chronic Kidney Disease in Children (CKiD) (10) studies, the Global Burden of Disease 
Study 2013, as well as registries that now exist in many countries provide important 
information, and more is required (11).
5Physiology International (Acta Physiologica Hungarica) 103, 2016
Editorial – World Kidney Day 2016
AKI may lead to CKD, according to selected adult population studies (12). The incidence 
of AKI among children admitted to an intensive care unit varies widely – from 8% to 89% 
(1). The outcome depends on the available resources. The results from projects such as the 
AWARE study, a five-nation study of AKI in children are awaited (13). Single center studies, 
as well as meta-analyses indicate that both AKI and CKD in children account for a minority 
of CKD worldwide (2, 3). However, it is increasingly evident that kidney disease in adulthood 
often springs from a childhood legacy (Fig. 1).
Fig. 1. The types and risks of kidney disease change across the lifecycle.  
The contribution of nephron number increases over the life cycle, in concert with events  
that provide direct insults and challenges to kidney health
Spectrum of Pediatric Kidney Diseases 
The conditions that account for CKD in childhood, with a predominance of congenital and 
hereditary disorders, differ substantially from those in adults. To date, mutations in more than 
150 genes have been found to alter kidney development or specific glomerular or tubular 
functions (14). Most of these genetic disorders present during childhood, and many lead to 
progressive CKD. Congenital anomalies of the kidney and urinary tract (CAKUT) account 
for the largest category of CKD in children (see Table II) and include renal hypoplasia/
dysplasia and obstructive uropathy. Important subgroups among the renal dysplasias are the 
cystic kidney diseases, which originate from genetic defects of the tubuloepithelial cells’ 
primary cilia. Many pediatric glomerulopathies are caused by genetic or acquired defects of 
the podocytes, the unique cell type lining the glomerular capillaries. Less common but 
important causes of childhood CKD are inherited metabolic disorders such as hyperoxaluria 
and cystinosis, and atypical hemolytic uremic syndrome, a thrombotic microangiopathy 
related to genetic abnormalities of complement, coagulation or metabolic pathways. 
In various classifications it is not clear how to categorize children who have suffered 
AKI and apparently recovered, or how and whether to include those children who have had 
perinatal challenges, likely resulting in a relatively low nephron number. 
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Table II. Etiology of chronic kidney disease in children
 CKD   ESRD
Etiology Percentage (Range) Etiology Percentage (Range)
CAKUT 48–59% CAKUT 34–43%
GN 5–14% GN 15–29%
HN 10–19% HN 12–22%
HUS 2–6% HUS 2–6%
Cystic 5–9% Cystic 6–12%
Ischemic 2–4% Ischemic 2%
Rare causes include congenital NS, metabolic diseases, cystinosis.
Miscellaneous causes depend on how such entities are classified.
CAKUT: Congenital anomalies of the kidney and urinary tract; GN: Glomerulonephritis;  
HN: Hypertension; HUS: Hemolytic uremic syndrome
Sources: from Harambat et al. CKD data are from NAPRTCS, the Italian Registry and the Belgian Registry. 
ESRD data are from ANZDATA, ESPN/ERA-EDTA, UK Renal Registry and the Japanese Registry.
Among children with childhood-onset end-stage renal disease (ESRD) glomerulopathies 
are slightly more and congenital anomalies less common (Table II), due to the typically more 
rapid nephron loss in glomerular disease. However, recent evidence suggests that many 
patients with milder forms of CAKUT may progress to ESRD during adulthood, peaking in 
the fourth decade of life (15).
There are national and regional differences in the types and course of both AKI and 
CKD during childhood and beyond. Death from kidney disease is higher in developing 
nations, and national and regional disparities in care and outcome must be addressed. Further, 
access to care is variable, depending on the region, the country and its infrastructure. By 
focusing on kidney disease in childhood, cost-effective solutions may be reached, as treating 
disease early and preemptively may prevent later, more advanced CKD. Expectations depend 
on the availability of care and management. Treating children, even from infancy, who have 
AKI and CKD that requires renal replacement therapy can be effective in mitigating the 
burden of kidney disease in adulthood. Doing so requires resources that focus on the most 
expeditious and cost-effective ways to deliver acute RRT in childhood.
Congenital Kidney Disease and Developmental Origins of Health and Disease,  
Renal Endowment and Implications
In regions where antenatal fetal ultrasounds are routine, many children with urologic 
abnormalities are identified antenatally, which permits early intervention. However, in much 
of the world, children with structural abnormalities are not identified until much later, when 
symptoms develop. While generalized screening for proteinuria, hematuria and urinary tract 
infections are carried out in some countries and regions, there is a lack of consensus as to its 
effectiveness. However, there is general agreement that children with antenatal ultrasound 
studies that indicate possible genitourinary anomalies, children with a family history of 
kidney disease, and children with signs such as failure to thrive or a history of urinary tract 
infection, voiding dysfunction or an abnormal appearing urine should be examined. Initial 
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screening would include a focused physical examination and a urine dipstick, formal 
urinalysis and a basic chemistry panel, followed by a more focused evaluation if indicated. 
Depending on the diagnosis, definitive therapy may be indicated. However, the evidence 
that therapy will slow progression of CKD in childhood remains limited. Angiotensin 
converting enzyme inhibitors, angiotensin receptor blockers, antioxidants and, possibly, 
dietary changes may be indicated, depending on the diagnosis. However, dietary changes 
need to permit adequate growth and development. The ESCAPE trial provided evidence that 
strict blood pressure control retards progression of CKD in children irrespective of the type 
of underlying kidney disease (16).
Some very young children may require renal replacement therapy in early infancy. 
Recent data pooled from registries worldwide indicate good survival, even when dialysis is 
required from neonatal age (2, 17). Kidney transplantation, the preferred renal replacement 
therapy in children, is generally suitable after 12 months of age, with excellent patient and 
allograft survival, growth and development. 
Evidence is accumulating that childhood-onset CKD leads to accelerated cardiovascular 
morbidity and shortened life expectancy. Ongoing large prospective studies such as the 
(Cardiovascular Comorbidity in Children with CKD (4C) study are expected to inform about 
the causes and consequences of early cardiovascular disease in children with CKD (18).
In addition to those children with congenital kidney disease, it is now known that 
perinatal events may affect future health in the absence of evident kidney disease in early life 
(19). Premature infants appear to be particularly at risk for kidney disease long after they are 
born, based both on observational cohort studies, as well as on case reports. Increasingly 
premature infants survive, including many born well before nephrogenesis is complete (20). 
The limited data available indicate that in the process of neonatal ICU care, such babies 
receive many nephrotoxins, and that those dying prior to discharge from the nursery have 
fewer and larger glomeruli (21). Additionally, those surviving have evidence of renal 
impairment that may be subtle (22). Even more concerning, abundant epidemiologic data 
indicate that persons born at term but with relatively low birth weights may be at high risk for 
hypertension, albuminuria and CKD in later life (23). When direct measurements are pursued, 
such persons, as adults, may have fewer nephrons, thus a low cardiorenal endowment. 
In focusing on children for World Kidney Day, we would note that it is key to follow 
kidney function and blood pressure throughout life in those persons born early or small-for-
dates. By doing so, and avoiding nephrotoxic medications throughout life, it may be possible 
to avert CKD in many people.
Resources and Therapeutics for Children –  
Differences from Therapeutics in Adults 
Disparities exist in the availability of resources to treat AKI in children and young people; 
consequently, too many children and young adults in developing nations succumb if AKI 
occurs. To address the problem the ISN has initiated the Saving Young Lives Project, which 
aims both to prevent AKI with prompt treatment of infection and/or delivery of appropriate 
fluid and electrolyte therapy, and to treat AKI when it occurs. This ongoing project in 
SubSaharan Africa and South East Asia, in which four kidney foundations participate equally 
(IPNA (International Pediatric Nephrology Association), ISN (International Society of 
Nephrology), ISPD (International Society for Peritoneal Dialysis), SKCF (Sustainable 
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Kidney Care Foundation)), focuses on establishing and maintaining centers for the care of 
AKI, including the provision of acute peritoneal dialysis. It links with the ISN’s 0 by 25 
project, which calls on members to ensure by 2025 that nobody dies from preventable and 
acute kidney injury. 
In view of the preponderance of congenital and hereditary disorders, therapeutic 
resources for children with CKD have historically been limited to a few immunological 
conditions. Very recently, progress in drug development in concert with advances in genetic 
knowledge and diagnostic capabilities has begun to overcome the long-standing ‘therapeutic 
nihilism’ in pediatric kidney disease. Atypical HUS, long considered ominous, with a high 
likelihood of progression to ESRD and post-transplantation recurrence, has turned into a 
treatable condition – with the advent of a monoclonal antibody that specifically blocks C5 
activation (24). Another example is the use of vasopressin receptor antagonists to retard cyst 
growth and preserve kidney function in polycystic kidney disease (25). First proven 
efficacious in adults with autosomal dominant polycystic kidney disease, therapy with 
vaptans holds promise also for the recessive form of the disease, which presents and often 
progresses to ESRD during childhood. 
However, patient benefit from pharmacological research breakthroughs is jeopardized 
on a global scale by the enormous cost of some of the new therapeutic agents. The quest for 
affordable innovative therapies for rare diseases will be a key issue in pediatric nephrology 
in the years to come.
The identification of children likely to benefit from novel therapeutic approaches will be 
greatly facilitated by the development of clinical registries that inform about the natural 
disease course, including genotype–phenotype correlations. Apart from disease-specific 
databases, there is also a need for treatment-specific registries. These are particularly relevant 
in areas where clinical trials are difficult to perform due to small patient numbers and lacking 
industry interest, as well as for therapies in need of global development or improvement. For 
instance, there is currently a large international gradient in the penetration and performance 
of pediatric dialysis and transplantation. Whereas pediatric patient and technique survival 
rates are excellent and even superior to those of adults in many industrialized countries, it is 
estimated that almost half of the world’s childhood population is not offered chronic renal 
replacement therapy (RRT) at all. Providing access to RRT for all children will be a 
tremendous future challenge. To obtain reliable information on the demographics and 
outcomes of pediatric RRT, the International Pediatric Nephrology Association (IPNA) is 
about to launch a global population-based registry. If successful, the IPNA RRT registry 
might become a role model for global data collection.
Transition from Pediatric to Adult Care
Transition of care for adolescents with kidney disease into an adult setting is critical both for 
patients and their caregivers. Non-adherence is a too-frequent hallmark of transition from 
pediatric to adult care for young patients with chronic disease states (26–28). Hence, 
considered steps combined with systematically defined procedures supported by validated 
pathways and credible guidelines must be in place to ensure successful outcomes. 
In the process of change from pediatric to adult care “transition,” which should occur 
gradually, must be distinguished from “transfer,” which is often an abrupt and mechanistic 
change in provider setting. Introducing the concept of transition should be preemptive, 
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starting months to years prior to the targeted time, as children move into adolescence and 
adulthood. The ultimate goal is to foster a strong relationship and individualized plan in the 
new setting that allows the patient to feel comfortable enough to report non-adherence and 
other lapses in care.
A transition plan must recognize that the emotional maturity of children with kidney 
disease may differ widely. Assessment of the caregiver and the family structure as well as 
cultural, social, and financial factors at the time of transition are key, including a realistic 
assessment of caregiver burden (4). The appropriate timing and format of transition may vary 
widely among different patients and in different settings; therefore, a flexible process without 
a set date and even without a delineated format may be preferred. 
Importantly, transition may need to be slowed, paused or even reversed temporarily 
during crises such as disease flares or progression, or if family or societal instability occurs. 
A recent joint consensus statement by the International Society of Nephrology (ISN) and 
International Pediatric Nephrology Association (IPNA) proposed steps consistent with the 
points just outlined, aiming to enhance the transition of care in kidney disease in clinical 
practice (29, 30). 
Call for Generating further Information and Action 
Given vulnerabilities of children with kidney disease including impact on growth and 
development and future life as an adult, and given the much greater proportion of children in 
developing nations facing resource constraints educating everyone involved is imperative in 
order to realign communications and actions (31, 32). These efforts should foster regional 
and international collaborations and exchange of ideas between local kidney foundations, 
professional societies, other not-for-profit organisations, and states and governments, so as to 
help empower all stakeholders to improve the health, well-being and quality of life of children 
with kidney diseases and to ensure their longevity into adulthood.
Until recently, however, the WHO consensus statement on non-communicable diseases 
(NCD) included cardiovascular disease, cancer, diabetes and chronic respiratory disease, but 
not kidney disease (33, 34). Fortunately, due, in part, to a global campaign led by the ISN, the 
Political Declaration on NCDs from the United Nations Summit in 2011 mentioned kidney 
disease under Item 19 (35). 
Increasing education and awareness about renal diseases in general and kidney disease 
in childhood in particular is consistent with the objectives of the WHO to reduce mortality 
from NCD with a 10-year target population level initiatives focusing on changes in life style 
(including tobacco use reduction, salt intake control, dietary energy control, and alcohol 
intake reduction) and effective interventions (including blood pressure, cholesterol and 
glycemic control). Heightened efforts are needed to realign and expand these multidisciplinary 
collaborations with more effective focus on early detection and management of kidney 
disease in children. Whereas the issues related to kidney disease may be overshadowed by 
other NCDs with apparently larger public health implications such as diabetes, cancer, and 
cardiovascular diseases, our efforts should also increase education and awareness on such 
overlapping conditions as cardiorenal connections, the global nature of the CKD and ESRD 
as major NCDs, and the role of kidney disease as the multiplier disease and confounder for 
other NCDs. White papers including consensus articles and blueprint reviews by world class 
experts can serve to enhance these goals (36). 
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